Endothelial Derived Hyperpolarization Factor and Vascular Control
Launched by UNIVERSITY OF OKLAHOMA · Dec 14, 2021
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a specific factor in our blood vessels, called endothelial derived hyperpolarization factor (EDHF), affects blood flow during times when our body's nervous system is more active, like during exercise or stress. Researchers want to find out if blocking this factor changes how blood vessels respond when the body's sympathetic nervous system is stimulated, which is often the case in healthy individuals. The goal is to better understand how EDHF works in regulating blood flow, which could help in treating heart and metabolic diseases linked to increased nerve activity.
To participate in this study, you need to be healthy, with a normal blood pressure and no history of heart or metabolic diseases. Specifically, you should be between the ages of 65 and 75, have a body mass index (BMI) under 30, and women must have regular menstrual cycles. If you smoke, use certain medications, or are pregnant, you wouldn't be eligible. Participants can expect to undergo safe and non-invasive tests to assess their blood vessel responses during rest and exercise. This research could lead to new treatments for conditions affecting blood flow and overall heart health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Normotensive (systolic blood pressure \< 130 mmHg and/or diastolic blood pressure \< 85 mmHg) individuals
- • Individuals free of cardiovascular disease and metabolic disease
- • Individuals free of any form of autonomic dysfunction
- • Individuals with a BMI under 30 kg/m²
- • Women that are premenopausal with a regular menstrual cycle (26-30 days)
- Exclusion Criteria:
- • Smokers, tobacco users (regular use in the last 6 months)
- • Individuals with a blood pressure greater than 130/85
- • Subjects who use Amiodarone, Sulphaphenazole
- • Subjects who use S-warfarin, Tolbutamine, Phenytoin, Lonafarnib
- • Cardiometabolic medication use (e.g. anti-hypertensives, insulin-sensitizing, statins)
- • Sex hormone replacement medical use (e.g. testosterone, estrogen, progesterone)
- • Pregnancy
About University Of Oklahoma
The University of Oklahoma, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a robust network of interdisciplinary experts and state-of-the-art facilities, the university fosters an environment that promotes scientific discovery and the development of new treatments. Its commitment to patient-centered research ensures that clinical trials not only adhere to the highest ethical standards but also aim to address pressing health challenges. By collaborating with various stakeholders, including industry partners and healthcare providers, the University of Oklahoma seeks to translate research findings into tangible benefits for communities, ultimately enhancing the quality of care and improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Norman, Oklahoma, United States
Patients applied
Trial Officials
Jeremy M Kellawan, PhD
Principal Investigator
University of Oklahoma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials